Response to the letter by Adams and Kwee, entitled: “Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma”

  • Elif Hindié
  • Charles Mesguich
  • Krimo Bouabdallah
  • Noël Milpied
Reply

References

  1. 1.
    Hindie E, Mesguich C, Bouabdallah K, Milpied N. Advanced Hodgkin’s lymphoma: end-of-treatment FDG-PET should be maintained. Eur J Nucl Med Mol Imaging. 2017;44:1254–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Canellos GP, Rosenberg SA, Friedberg JW, Lister TA, Devita VT. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32:163–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Merli F, Luminari S, Gobbi PG, Cascavilla N, Mammi C, Ilariucci F, et al. Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi. J Clin Oncol. 2016;34:1175–81.CrossRefPubMedGoogle Scholar
  4. 4.
    Adams HJ, Kwee TC. Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2017. doi:10.1007/s00259-017-3771-8.Google Scholar
  5. 5.
    Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017;18:454–63.CrossRefPubMedGoogle Scholar
  6. 6.
    Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin’s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Bakhshi S, Bhethanabhotla S, Kumar R, Agarwal K, Sharma P, Thulkar S, et al. Posttreatment PET/CT rather than interim PET/CT using Deauville criteria predicts outcome in pediatric Hodgkin lymphoma: a prospective study comparing PET/CT with conventional imaging. J Nucl Med. 2017;58:577–83.CrossRefPubMedGoogle Scholar
  8. 8.
    Barnes JA, LaCasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin’s lymphoma. Ann Oncol. 2011;22:910–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51:1337–43.CrossRefPubMedGoogle Scholar
  10. 10.
    Filippi AR, Botticella A, Bello M, Botto B, Castiglione A, Gavarotti P, et al. Interim positron emission tomography and clinical outcome in patients with early stage Hodgkin lymphoma treated with combined modality therapy. Leuk Lymphoma. 2013;54:1183–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Jalali A, Ha FJ, Chong G, Grigg A, McKendrick J, Schwarer AP, et al. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era. Ann Hematol. 2016;95:809–16.CrossRefPubMedGoogle Scholar
  12. 12.
    Lopci E, Burnelli R, Guerra L, Cistaro A, Piccardo A, Zucchetta P, et al. Postchemotherapy PET evaluation correlates with patient outcome in paediatric Hodgkin’s disease. Eur J Nucl Med Mol Imaging. 2011;38:1620–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Markova J, Kahraman D, Kobe C, Skopalova M, Mocikova H, Klaskova K, et al. Role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone. Leuk Lymphoma. 2012;53:64–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Mesguich C, Cazeau AL, Bouabdallah K, Soubeyran P, Guyot M, Milpied N, et al. Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation. Br J Haematol. 2016;175:652–60.CrossRefPubMedGoogle Scholar
  15. 15.
    Straus DJ, Johnson JL, LaCasce AS, Bartlett NL, Kostakoglu L, Hsi ED, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. 2011;117:5314–20.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin’s disease and aggressive non-Hodgkin’s lymphoma: a systematic review. J Nucl Med. 2008;49:13–21.CrossRefPubMedGoogle Scholar
  17. 17.
    Adams HJ, Nievelstein RA, Kwee TC. Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy. Ann Hematol. 2016;95:1–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, et al. Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012;39:4–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, et al. In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. J Clin Oncol. 2014;32:2705–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Van Den Neste E, Casasnovas O, Andre M, Touati M, Senecal D, Edeline V, et al. Classical Hodgkin’s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98:1185–95.CrossRefGoogle Scholar
  21. 21.
    Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579–86.CrossRefPubMedGoogle Scholar
  22. 22.
    Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, et al. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017. doi:10.1093/annonc/mdx097.Google Scholar
  24. 24.
    Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, et al. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2017;15:608–38.CrossRefGoogle Scholar
  25. 25.
    Jakobsen LH, Hutchings M, de Nully Brown P, Linderoth J, Mylam KJ, Molin D, et al. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. Br J Haematol. 2016;173:236–44.CrossRefPubMedGoogle Scholar
  26. 26.
    Moulin-Romsee G, Hindie E, Cuenca X, Brice P, Decaudin D, Benamor M, et al. (18)F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging. Eur J Nucl Med Mol Imaging. 2010;37:1095–105.CrossRefPubMedGoogle Scholar
  27. 27.
    El-Galaly TC, d’Amore F, Mylam KJ, de Nully Brown P, Bogsted M, Bukh A, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30:4508–14.CrossRefPubMedGoogle Scholar
  28. 28.
    Cerci JJ, Trindade E, Pracchia LF, Pitella FA, Linardi CC, Soares J Jr, et al. Cost effectiveness of positron emission tomography in patients with Hodgkin’s lymphoma in unconfirmed complete remission or partial remission after first-line therapy. J Clin Oncol. 2010;28:1415–21.CrossRefPubMedGoogle Scholar
  29. 29.
    Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283–94.CrossRefPubMedGoogle Scholar
  30. 30.
    Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35:2125–32.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Elif Hindié
    • 1
    • 2
  • Charles Mesguich
    • 1
  • Krimo Bouabdallah
    • 3
  • Noël Milpied
    • 3
  1. 1.Department of Nuclear MedicineBordeaux University HospitalBordeauxFrance
  2. 2.Hôpital Haut-LévêquePessacFrance
  3. 3.Department of Hematological OncologyBordeaux University HospitalBordeauxFrance

Personalised recommendations